Work

A phase I study of the safety, tolerability, pharmacokinetics, and immunoregulatory activity of urelumab (BMS-663513) in subjects with advanced and/or metastatic solid tumors and relapsed/refractory B-cell non-Hodgkin’s lymphoma (B-NHL).

Year: 2013

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2013.31.15_suppl.tps3107

Authors: Ignacio Melero, Tara C. Gangadhar, Holbrook Edwin Kohrt, Neil Howard Segal, Theodore Logan, Walter John Urba, F. Stephen Hodi, Patrick Alexander Ott, Jose Luis Perez-Gracia, Jedd D. Wolchok, Aadhar Shah, John F. Kurland, Lewis J. Cohen, Ronald Levy, Jon M. Wigginton, Stacie M. Goldberg

Institutions: Clinica Universidad de Navarra, University of Pennsylvania, Stanford Cancer Institute, Stanford University, Memorial Sloan Kettering Cancer Center, Indiana University Health, Indiana University Indianapolis, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Providence Portland Medical Center, Dana-Farber Cancer Institute, Bristol-Myers Squibb (United States), Stanford Medicine

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2601805960

Cites:

Cited by: 13

Related to: 10